600216 浙江醫藥
按盤價 
16.750 -0.890 (-5.045%) | 2025/09 - 九個月 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | 8.599 | 11.446 | 4.549 | 5.982 | 12.706 |
| 總資產報酬率 ROA (%) | 6.682 | 8.734 | 3.408 | 4.323 | 9.077 |
| 投入資產回報率 ROIC (%) | 7.868 | 10.523 | 4.160 | 5.411 | 11.300 | 邊際利潤分析 |
| 銷售毛利率 (%) | 37.494 | 42.332 | 32.387 | 34.470 | 40.851 |
| 營業利潤率 (%) | 15.657 | 13.046 | 4.877 | 6.218 | 12.920 |
| 息稅前利潤/營業總收入 (%) | 14.235 | 12.878 | 4.437 | 5.587 | 13.656 |
| 淨利潤/營業總收入 (%) | 12.945 | 10.882 | 3.551 | 4.468 | 9.689 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 101.043 | 118.883 | 30.963 | 128.977 | 103.750 |
| 價值變動淨收益/利潤總額(%) | 2.555 | -2.442 | -3.745 | -11.500 | 8.109 |
| 營業外收支淨額/利潤總額(%) | -0.190 | -0.893 | -4.646 | -2.692 | -2.246 | 償債能力分析 |
| 流動比率 (X) | 2.788 | 2.563 | 2.260 | 2.294 | 1.995 |
| 速動比率 (X) | 2.013 | 1.733 | 1.449 | 1.485 | 1.376 |
| 資產負債率 (%) | 20.689 | 21.221 | 21.856 | 21.900 | 26.733 |
| 帶息債務/全部投入資本 (%) | 7.356 | 6.265 | 7.443 | 8.284 | 9.517 |
| 股東權益/帶息債務 (%) | 1,235.871 | 1,470.285 | 1,232.741 | 1,100.412 | 942.674 |
| 股東權益/負債合計 (%) | 378.014 | 363.724 | 344.798 | 340.092 | 262.045 |
| 利息保障倍數 (X) | -10.219 | -243.513 | -19.773 | -11.943 | 13.389 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 62.638 | 55.285 | 58.895 | 60.809 | 51.636 |
| 存貨周轉天數 (天) | 132.685 | 137.940 | 136.804 | 130.911 | 111.783 |
| 備註： | 即時報價更新時間為 10/03/2026 16:29 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
